In November, FACCNE launched its new Leaders Series to meet with C-level Executives whose companies, startups, and initiatives are boosting the American market.

For Leaders Series #1, we had the pleasure to interview Julie Chapon & Lucie Basch, Co-Founders of Yuka and Too Good To Go.

In December, we hosted Leaders Series #2, a conversation with Adrien Nussenbaum, CEO of Mirakl Inc., the global leader in online marketplace solutions.

This month, we are very excited to announce Leaders Series #3 with Patrick Tricoli, CEO of Nanobiotix Corp. This discussion will be moderated by Frederic Chereau, President & CEO of LogicBio Therapeutics.

Join us on March 4, 2021 at 1PM EST/19H Paris Time

This event is FREE and OPEN TO ALL

REGISTER HERE

The discussion will give us the opportunity to get to know more about Nanobiotix and its leading position in clinical-stage nanomedicine. Nanobiotix has made some monumental achievements, including but not limited to,  launching on NASDAQ, successful testing of NBTXR3 injection in cancer patients, and global expansion. See their Key Development Milestones for 2021 here. Additionally, this event will be a chance to learn more about Patrick Tricoli’s journey as a leader in pharmaceuticals industry. Our Leaders Series has been a wonderful opportunity for CEOs to connect and speak directly about their journey so far and what they see for the future of their company, industry, and themselves. You won’t want to miss it!

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to  significantly change patient outcomes by bringing nanophysics to the heart of the cell. The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and  generalized solutions to address unmet medical needs and challenges.  Nanobiotix’s novel, potentially first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits  for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to  cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg:  NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are in Paris,  France, with a U.S. affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.

Patrick Tricoli is the current CEO of Nanobiotix Corp., the Nanobiotix US affiliate in Cambridge (MA) and  EVP, Global Head of Business Development for the company. Patrick has built the Nanobiotix US presence,  beginning in 2014, while cultivating cross-industry relationships.

Prior to Nanobiotix Patrick was well known for his lead roles at Sanofi in Partnering and Innovation R&D,  and subsequently Head of External Innovation Europe, spanning 15 years, Europe, Asia, and the US markets where he led multiple teams in developing strong international BD relationships, Corporate  Development strategies, and collaborative R&D partnership.

Patrick Tricoli ‘s background is R&D academic and industry including the Medical Research Division of  Lederle Pearl River NY -today Pfizer- before he joint Synthélabo in 1991. He also currently serves as a Foreign Trade Advisor New England for the French government since 2017 and as President of Curadigm Advisory Board.  Finally, Patrick is a Pharm D, Master in Pharmacology and Pharmacokinetic and Executive MBA from ESCP Europe.

Frederic Chereau is LogicBio’s President and CEO since 2016. He is a global healthcare executive with more than 25 years’ experience leading groundbreaking biotherapeutics companies as they grow, moving products from proof-of-concept through clinical trials toward successful commercialization. Prior, Frederic was President and COO of aTyr Pharma (a publicly traded company developing innovating therapeutics – San Diego, CA); SVP and Angioedema Franchise Lead at Shire (now Takeda – Cambridge, MA) and President and CEO of Pervasis Therapeutics (acquired by Shire Plc). Before that, he was an executive at Genzyme (now Sanofi-Genzyme, Cambridge, MA) for a decade, where he ultimately ran the cardiovascular business unit.

Mr. Chereau serves on the Board of Directors of Dynacure, a biotechnology company based in Strasbourg, France, and on the Strategic Advisory Board of La Rochelle Business School. He holds a bachelor’s degree in Physics from the University of Paris, a master’s degree in management from La Rochelle Business School, and an MBA from INSEAD, Fontainebleau, France, and Singapore.